Advertisements

Димедрол-УБФ

Quick links to important sections

Димедрол-УБФ

Advertisements

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Димедрол-УБФ

Property Description
Active ingredient Diphenhydramine Hydrochloride (INN)
Form Tablets; Solution for injection
Pharmacological class First-generation H1-Antihistamine
Common use Allergic symptom relief; Sedation
Origin Synthetic (Ethanolamine derivative)

Димедрол-УБФ is a synthetic medicinal product whose active ingredient is Diphenhydramine (Diphenhydramine Hydrochloride), fundamentally classified as a first-generation H1-antihistamine. The substance belongs to the chemical class of aminoalkyl ethers, also known as ethanolamine derivatives. Within the Anatomical Therapeutic Chemical (ATC) system, it is identified by the code R06AA02. The designation as a first-generation agent is a clinically recognized property due to its ability to easily cross the blood-brain barrier, which dictates its distinct effects on the central nervous system.

Composition and General Purpose of Diphenhydramine

Димедрол-УБФ is consistently manufactured as a single-ingredient product, containing only Diphenhydramine Hydrochloride combined with necessary inactive pharmaceutical excipients. This preparation is supplied for systemic administration in two main forms: as tablets for oral intake and as a sterile aqueous solution for injection (parenteral route), allowing for flexible use in varied clinical settings.

The general purpose of the medication leverages its dual pharmacological activity: it acts as a competitive antagonist at the H1-receptors to mitigate common allergic symptoms, which means it helps reduce the body's reaction to allergens. Furthermore, it exhibits notable anticholinergic properties. This secondary action is responsible for the distinct sedative effect, making the substance generally useful for short-term assistance with sleep or motion-related symptoms.

Regulatory References

  1. Diphenhydramine Drug Information (MedlinePlus)
Advertisements

What side effects are possible with Димедрол-УБФ?

Possible Side Effects and Safety Information

The safety profile of Diphenhydramine (the active ingredient in Димедрол-УБФ) is structured by regulatory agencies around its well-documented effects on the central nervous and anticholinergic systems. Official labeling classifies adverse reactions according to frequency and affected body systems, providing a formal overview of the medicine's risk profile.


Adverse Reaction Classification

Adverse Reaction Type Examples (As Listed in Regulatory Sources)
Most Frequent Sedation, somnolence, dizziness, dry mouth, disturbed coordination, and fatigue.
Other Listed Effects Nausea, vomiting, constipation, blurred vision, tachycardia, and hypotension.
Rare/Serious Reactions Anaphylactic shock, seizures, and blood dyscrasias (e.g., hemolytic anemia).

The most frequent adverse reactions primarily involve the Nervous System and the Gastrointestinal System. These effects, particularly sedation and somnolence, are generally noted in official documents as being most pronounced at the start of treatment.

Population-Specific Safety Notes

The official profile includes specific safety considerations for certain patient groups. Older adults are noted to have an increased risk of confusion, sedation, dizziness, and adverse anticholinergic effects like urinary retention. Conversely, in pediatric patients, the potential for paradoxical excitation (restlessness and insomnia) is specifically documented in regulatory labeling. Safety restrictions also advise caution for individuals with pre-existing conditions such as narrow-angle glaucoma, symptomatic prostatic hypertrophy, or pyloroduodenal obstruction due to the drug's anticholinergic properties.

Advertisements

Overdose and Emergency Response

The regulatory overdose profile for Diphenhydramine is defined by its potential for severe central nervous system (CNS) and cardiotoxicity. Documented overdose manifestations include both CNS depression, such as profound drowsiness and coma, and CNS stimulation, presenting as agitation, hallucinations, and convulsions. Anticholinergic effects are also listed, specifically fixed or dilated pupils (mydriasis), flushing, dry mouth, and elevated body temperature.

Overdoses are associated with life-threatening systemic outcomes, including serious cardiac arrhythmias, cardiovascular collapse, and the risk of death. Pediatric patients are particularly susceptible to CNS stimulation, with overdosage causing an elevated risk of hallucinations, convulsions, or death.

Immediate medical attention is required in all suspected overdose cases. Urgent contact with emergency services or a Poison Control Center is specifically mandated if an individual experiences a seizure, has trouble breathing, collapses, or is difficult to awaken. Management of a confirmed overdose is supportive and symptomatic, involving measures such as the administration of activated charcoal and monitoring of vital signs and ECG. Regulatory documents state that no specific antidote is known, and the use of stimulants is explicitly prohibited in the management of toxicity.

Advertisements

Therapeutic Uses of Димедрол-УБФ

What Димедрол-УБФ Treats: Main Uses and Benefits

The medication is used across multiple symptomatic domains, including allergy, sleep, and motion sickness. It is commonly used when short-term symptomatic assistance is needed to ease the burden of distressing acute or episodic manifestations. The substance is relevant for easing symptoms related to inflammatory or irritative states such as pronounced itching, sneezing, and runny nose, as well as for symptoms that interfere with daily functioning like sleeplessness.

Managing Symptoms Across Key Domains

The therapeutic application of Димедрол-УБФ is relevant for managing symptoms across conditions presenting with acute episodes. The primary uses include providing relief for allergic symptoms, temporary assistance for sleep disturbances, supportive management of motion sickness, and management of specific acute involuntary muscle contractions (extrapyramidal symptoms). This provides support that helps ease the overall symptom burden during acute or episodic changes.

“The application is relevant for easing physical discomfort caused by heightened symptoms and providing symptomatic support for temporary functional strain.”

Quick Fact: Symptomatic support for Pruritus and Restlessness The medication is commonly used to help with noticeable symptoms that cluster into patterns, such as pervasive itching accompanying hives, or the restlessness that interferes with sleep initiation.

Supportive Comfort and Stability

The medication contributes to improved day-to-day comfort by temporarily easing distress and assisting with maintaining comfort and stability during symptomatic periods. In clinical scenarios, it is generally applied to provide symptomatic support for severe systemic discomfort or used in situations requiring short-term symptom stabilization during travel.

Regulatory References

  1. NIH MedlinePlus overview of Diphenhydramine
Advertisements

Eligibility and Restrictions for Use

Official Population Eligibility for Diphenhydramine

Regulatory agencies define specific population groups for whom use of Diphenhydramine (the active ingredient in Димедрол-УБФ) is restricted or prohibited. The medicine is contraindicated in certain patient populations to prevent serious risk.

Absolute Contraindications

Use is prohibited for neonates or premature infants and for nursing mothers. The drug is also contraindicated in patients with a known hypersensitivity to diphenhydramine or chemically similar antihistamines, as well as those with stenosing peptic ulcer or pyloroduodenal obstruction. Concomitant use with Monoamine Oxidase Inhibitors (MAOIs) is also strictly prohibited.

Age and Condition Restrictions

While use is generally approved for adults and children over 2 years of age, caution is advised. The drug is not recommended for self-medication in children under 6 years of age. Use in older adults (ge 60 years) requires caution due to increased risk of side effects. Eligibility is also restricted and requires caution in patients with conditions like narrow-angle glaucoma, bronchial asthma, hyperthyroidism, cardiovascular disease, or those with issues leading to urinary retention. During pregnancy, it is classified as Pregnancy Category B, but its use is not recommended unless clearly needed, and it should be avoided in the third trimester.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Diphenhydramine (the active ingredient in Димедрол-УБФ) defines restrictions based on additive effects and metabolic processing.

Interaction Scope
Medicinal product categories with documented interactions Monoamine Oxidase Inhibitors (MAOIs); Central Nervous System (CNS) Depressants; Other Anticholinergic agents (e.g., sedatives, tranquilizers, opioids) [FDA].
Timing-based interaction rules Co-administration with MAOIs is contraindicated, with regulatory documentation requiring a 14-day separation period after MAOI discontinuation [FDA].
Interaction-related restrictions Alcohol (ethanol) must be avoided due to the documented additive effect resulting in enhanced CNS depression [NIH].

Official Interaction Statements

  • Co-administration with MAOIs, or use within 14 days of stopping MAOI therapy, is prohibited due to the potential for intensified and prolonged anticholinergic effects.
  • Additive CNS depression occurs with the concurrent use of other CNS depressants, including opioids and benzodiazepines, which can heighten effects like sedation.
  • The risk of additive anticholinergic adverse effects (e.g., dry mouth, urinary retention) is increased when combined with other anticholinergic medicines.
  • Diphenhydramine is identified as a substrate for and a competitive inhibitor of the hepatic enzyme CYP2D6, indicating that co-administration with strong CYP2D6 inhibitors may increase the plasma concentration of Diphenhydramine.
  • Interaction effects, such as dizziness and sedation, are noted to be more pronounced when combined with other interacting agents in the elderly patient population [NIH].
Advertisements

Mechanism of Action

The pharmacological action of Димедрол-УБФ (Diphenhydramine) is defined by its ability to modulate multiple high-affinity biological targets, primarily functioning as a non-selective first-generation antihistamine.

Dual Suppression of Histaminergic Pathways

This core mechanism involves acting as a competitive inverse agonist at the Histamine H1 Receptor (H1R), both peripherally and centrally. Peripherally, this action modifies early molecular steps that limit the downstream effects of histamine on vascular and sensory tissue, which results in the modulation of signaling within inflammatory pathways. Centrally, the molecule's high lipophilicity ensures rapid access to brain tissue. This central H1R suppression contributes to dampening the histaminergic tone that regulates wakefulness, which results in a physiological consequence of decreased central arousal.


Modulation via Anticholinergic Mechanism

A significant secondary domain is the antagonism at muscarinic acetylcholine receptors ( mAChR). This action alters signaling dynamics in the cholinergic system, which results in the inhibition of parasympathetic and central cholinergic signaling. This is relevant in contexts involving heightened activity of the vestibular system and the associated nerve pathways that influence equilibrium and the **medullary chemoreceptor trigger zone.***

Advertisements

Dosage and Administration Information

The instructions for using Diphenhydramine (the active ingredient in Димедрол-УБФ) define the methods, dose limits, and timing for administration.

Routes and Dosing

Administration may be via the Oral (PO) route using tablets or liquid forms, or via the Parenteral route using the solution for Intramuscular (IM) or Intravenous (IV) injection. Parenteral administration is typically reserved for situations where the oral route is impractical or contraindicated.

Population Standard Dose Range Maximum Daily Dose (24 hrs)
Adults (Oral) 25 mg to 50 mg per dose 300 mg
Adults (Parenteral) 10 mg to 50 mg per dose (up to 100 mg may be required) 400 mg

Frequency and Contextual Instructions

Frequency: Dosing for general use is typically scheduled every 4 to 6 hours as needed. When used for temporary assistance with sleep, the dose is taken once daily, 30 minutes before bedtime. For motion sickness prophylaxis, the initial dose should be administered 30 minutes prior to exposure to motion.

Administration: Oral forms may be taken with or without food. For IV injection, the solution must be administered slowly, at a rate generally not exceeding 25 mg per minute.

Population-Specific Guidance

Older Adults: Guidance suggests that a lower initial dose is generally advisable in geriatric patients.

Pediatric Patients: Parenteral dosing is determined by body weight or surface area, often calculated as 5 mg/kg/24 hr or 150 mg/m^2/24 hr, divided into four doses. The maximum daily parenteral dose for this group is 300 mg.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Димедрол-УБФ

Evidence for Use in Allergic Symptom Relief

Research has examined this medicine in contexts related to allergic symptoms, such as sneezing, itching, and runny nose, utilizing short-term Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies primarily examined patient-reported outcomes describing perceived discomfort and monitored outcomes linked to inflammatory or irritative states. Studies monitored symptom intensity or variability over brief periods, with findings describing patterns observed in the study populations. The evidence highlights that follow-up durations were limited, typically monitoring outcomes over a few days up to two weeks, meaning there is limited information for long-term outcomes.


Evidence for Use in Temporary Sleep Assistance

The agent was evaluated in research scenarios related to temporary sleep assistance for adults experiencing mild or short-term difficulty sleeping. The research exploring short-term symptom changes has mainly utilized double-blind RCTs and subsequent Meta-analyses. These studies explored outcomes reflecting daily functioning and temporary physiological imbalance, specifically focusing on sleep parameters. Research highlights changes measured during the study period, with some findings indicating that observed changes in sleep parameters were modest. Certain systematic reviews have reported that the measurements taken during these studies may fall below established thresholds considered to indicate clinically significant change. Certainty remains low regarding the findings related to this agent for use in the older adult populations.


What is Still Uncertain About Димедрол-УБФ Research

Research highlights that subgroup findings are uncertain, and data are still emerging in several key areas. The sample sizes were modest in some of the foundational studies, and evidence quality varies across studies depending on the specific application and context under investigation. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes. The evidence highlights what is known, as well as what is still uncertain, meaning research does not determine whether an individual will respond similarly to the patterns observed in the studies.

Key Studies & References

  1. American Geriatrics Society 2022 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Димедрол-УБФ (FAQ)


Q: How quickly does the effect of Димедрол-УБФ usually start?

Official documentation describes the active ingredient as being quickly absorbed after an oral dose. The maximum effect is generally observed in approximately one hour after the medication is taken. This period reflects when the active ingredient's concentration is typically highest in the blood.


Q: How long does the effect of Димедрол-УБФ typically last?

The duration of activity for an average dose is typically described in regulatory documents as lasting from four to six hours. This duration aligns with the typical interval for administration of the dose.


Q: What kind of side effects are most commonly reported for Димедрол-УБФ?

According to official regulatory labeling, the most frequent side effects reported include feelings of sedation, somnolence (drowsiness), dizziness, fatigue, and disturbed coordination. These effects are often noted as being most pronounced when treatment is first started.


Q: Is it normal to feel dry mouth after taking Димедрол-УБФ?

Yes, dryness of the mouth, nose, and throat are listed in official adverse reaction reports as one of the most frequent effects. This occurrence is attributed to the medication's anticholinergic properties, which affect the body's natural signaling.


Q: What happens if I forget to take a dose of Димедрол-УБФ?

General official guidance focuses on taking the medication exactly as directed on the product label or as outlined by a healthcare provider. Official documentation does not provide specific instructions regarding the management of a missed dose.


Q: Can children use Димедрол-УБФ?

Regulatory documents state that use is prohibited (contraindicated) in neonates and premature infants. While generally approved for children over two years of age, official guidance notes that children under 12 years should typically only use the medication under a healthcare provider's direction.


Q: What is the difference between Димедрол-УБФ and second-generation antihistamines?

Димедрол-УБФ is defined as a first-generation antihistamine. The key distinction, as noted in regulatory descriptions, is that it possesses significant sedative and anticholinergic effects. These properties allow it to cross the blood-brain barrier easily, leading to the pronounced central nervous system effects that are less common with newer, second-generation agents.


Q: Is it safe to use Димедрол-УБФ during pregnancy according to official documents?

Official documentation classifies the active ingredient as Pregnancy Category B. However, regulatory guidance also notes that its use is not recommended unless clearly needed and advises that the medication should be avoided during the third trimester of pregnancy.


Q: What is the guidance regarding using Димедрол-УБФ while breastfeeding?

The use of this medicine is prohibited (contraindicated) for nursing mothers. This restriction is documented in regulatory labeling due to the potential for adverse effects on the infant.


Q: Does taking Димедрол-УБФ affect the results of allergy skin tests?

As an antihistamine, the medicine works by competing with histamine at cell receptor sites. Official guidance advises that this activity may suppress the body’s reaction to skin testing, which should be taken into account when interpreting the results.


Q: Do studies exist regarding the safety profile of Димедрол-УБФ in the elderly?

Yes, official guidance documents and pharmacokinetic data specifically address use in older adults. These sources note that geriatric patients have an increased risk of side effects such as confusion and sedation, and a prolonged rate of elimination compared to younger adults.


Q: What is the guidance regarding using Димедрол-УБФ for itchiness (pruritus)?

Official documentation lists the active ingredient as being suitable for mild, uncomplicated allergic skin manifestations, such as hives (urticaria) and angioedema. This specifically includes providing relief from the related itching (pruritus).


Q: Does official labeling mention using Димедрол-УБФ for relief from cold symptoms?

Yes, official labeling and consumer information include use for the temporary relief of certain symptoms commonly associated with the common cold.


Q: Are changes to lifestyle (like diet) recommended while using Димедрол-УБФ?

General advice suggests that if you experience dry mouth, chewing sugarless gum or staying hydrated with water may provide relief. Official documents do not generally include recommendations for specific diet changes while using the medicine.


Q: Are there specific food items or drinks noted to interact with Димедрол-УБФ?

Alcohol is explicitly advised to be avoided because its consumption, when combined with this medication, can lead to an additive depressant effect, increasing drowsiness and other side effects. No specific food items are typically noted as interacting.


Q: How is Димедрол-УБФ officially classified in terms of drug schedules or control?

Diphenhydramine, the active ingredient, is generally not classified as a controlled substance under the U.S. DEA's Controlled Substances Act. Depending on the country and formulation, it is typically widely available as an over-the-counter (OTC) or prescription product.


Q: Can people with liver issues use Димедрол-УБФ?

Official documents advise that subjects with hepatic dysfunction (liver issues) should exercise caution when using this product. The medication is metabolized by the liver, and a prolonged half-life has been noted in patients with chronic liver disease.


Q: Is it described that Димедрол-УБФ can affect appetite?

Official regulatory labeling includes anorexia (loss of appetite) as a documented adverse reaction that affects the gastrointestinal system.


Q: Does official guidance warn against combining Димедрол-УБФ with pain relievers (analgesics)?

Regulatory guidance warns that combining it with pain relievers that are also classified as CNS depressants (such as certain opioids or prescription analgesics) can increase the risk of sedation and extreme tiredness.


Q: Do warnings exist about using Димедрол-УБФ with certain herbal supplements?

Official warnings advise seeking guidance from a healthcare provider before combining the drug with any supplements. Specific caution is noted for herbal remedies that are known to cause similar side effects, such as drowsiness or dry mouth.


Q: What should be done in case of accidentally taking too much Димедрол-УБФ?

Official guidance documents typically note that in the event of suspected accidental overdose, emergency medical services or a poison control center should be contacted immediately for direction.


Q: What is the maximum recommended period for using Димедрол-УБФ?

When used for temporary assistance with sleep, official guidance suggests use for no more than seven to ten consecutive nights. Official guidance documents caution that continued use beyond this period is not generally recommended.

Advertisements

How should Димедрол-УБФ be stored and disposed of?

How to Store and Dispose of Димедрол-УБФ?

The storage and disposal requirements for Diphenhydramine Hydrochloride (the active ingredient) are defined by official regulatory labeling to ensure product stability and safety.

Mandatory Storage and Handling

Category Regulatory Requirement
Temperature Store at Controlled Room Temperature ( 20 extdegree C to 25 extdegree C).
Protection Protect from light and keep from freezing.
Container Keep the container tightly closed and store out of the reach of children.

Disposal Instructions

Unused or expired medication must be disposed of in accordance with all local and national regulations. Official guidance recommends against flushing the product down the toilet and instead advises mixing it with an unappealing substance in a sealed bag before placing it in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Димедрол-УБФ found in:

A-Z Index: